SINUVA (mometasone furoate) plays an important role in a stepwise approach to treating CSwNP скачать в хорошем качестве

SINUVA (mometasone furoate) plays an important role in a stepwise approach to treating CSwNP

ARS Summer Sinus Symposium 2021 Panel Discussion: Moving Beyond Conventional Treatments of Nasal Polyps – The Role of Localized Drug Delivery and Biologics with Dr. Martin Citardi, Dr. Keith Matheny & Dr. Sanjeet Rangarajan -------------------------------- SINUVA Indication & Important Safety Information INDICATION SINUVA Sinus Implant is a corticosteroid-eluting (mometasone furoate) implant indicated for the treatment of nasal polyps, in patients ≥ 18 years of age who have had ethmoid sinus surgery. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Patients with known hypersensitivity to mometasone furoate and any of the ingredients of the SINUVA Sinus Implant. WARNINGS AND PRECAUTIONS Local Effects: Monitor nasal mucosa adjacent to the SINUVA Sinus Implant for any signs of bleeding (epistaxis), irritation, infection, or perforation. Avoid use in patients with nasal ulcers or trauma. Ocular Effects: Monitor patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts closely. Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, and angioedema have been reported with the use of corticosteroids. Immunosuppression: Patients taking corticosteroids are more susceptible to a more serious or even fatal course of chickenpox or measles than healthy individuals. Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.  Hypercorticism and Adrenal Suppression: If corticosteroid effects such as hypercorticism and adrenal suppression appear in patients, consider sinus implant removal. There are no studies evaluating repeat implantation of the SINUVA Sinus Implant. ADVERSE REACTIONS The most common adverse reactions observed (+1% of subjects and that occurred more frequently in the treatment group compared to control) in clinical studies were asthma, headache, epistaxis, presyncope, bronchitis, otitis media, and nasopharyngitis. Rx only. Please see Full Prescribing Information for SINUVA. https://www.sinuva.com/PI